Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients treated with low glucose degradation product (GDP) solution. The effects of low GDP solution on body fluid status and arterial pulse wave velocity (PWV) have not been studied.We randomly assigned 68 incident PD patients to low GDP (Intervention Group) or conventional solutions (Control Group); 4 dropped off before they received the assigned treatment. Patients were followed for 52 weeks for changes in ultrafiltration, residual renal function, body fluid status and arterial PWV.After 52 weeks, Intervention Group had higher overhydration (3.1 ± 2.6 vs 1.9 ± 2.2 L, p = 0.045) and extracellular water volume (17.7 ± 3.9 vs 15.8 ± 3.1 L, p = 0.034) tha...
BackgroundBiocompatible peritoneal dialysis (PD) solutions, including neutral pH, low glucose degrad...
Glucose-based peritoneal dialysis (PD) solutions are the mainstay of therapy for PD patients, yet ar...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
Background Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) pa...
Long-term exposure to a high glucose concentration in conventional peritoneal dialysis (PD) solution...
Neutral-pH peritoneal dialysates, with reduced glucose degradation products (GDPs), have been develo...
For patients on peritoneal dialysis (PD), the development of peritonitis, the decline of residual ki...
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (bio...
¤ Background: Long-term peritoneal dialysis (PD) is asso-ciated with the development of various stru...
The clinical benefits of using "biocompatible" neutral pH solutions containing low levels of glucose...
BACKGROUND: The local peritoneal effects of low-glucose degradation product (GDP)-containing periton...
♦ Background: The use of pH-neutral peritoneal dialysis (PD) fluids low in glucose degradation produ...
BACKGROUND: Glucose degradation products (GDPs) are cytotoxic in vitro and potentially toxic in vivo...
Session: Peritoneal dialysis: SU380INTRODUCTION AND AIMS: New peritoneal dialysis fluids (PDF) such ...
BackgroundBiocompatible peritoneal dialysis (PD) solutions, including neutral pH, low glucose degrad...
Glucose-based peritoneal dialysis (PD) solutions are the mainstay of therapy for PD patients, yet ar...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
Background Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) pa...
Long-term exposure to a high glucose concentration in conventional peritoneal dialysis (PD) solution...
Neutral-pH peritoneal dialysates, with reduced glucose degradation products (GDPs), have been develo...
For patients on peritoneal dialysis (PD), the development of peritonitis, the decline of residual ki...
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (bio...
¤ Background: Long-term peritoneal dialysis (PD) is asso-ciated with the development of various stru...
The clinical benefits of using "biocompatible" neutral pH solutions containing low levels of glucose...
BACKGROUND: The local peritoneal effects of low-glucose degradation product (GDP)-containing periton...
♦ Background: The use of pH-neutral peritoneal dialysis (PD) fluids low in glucose degradation produ...
BACKGROUND: Glucose degradation products (GDPs) are cytotoxic in vitro and potentially toxic in vivo...
Session: Peritoneal dialysis: SU380INTRODUCTION AND AIMS: New peritoneal dialysis fluids (PDF) such ...
BackgroundBiocompatible peritoneal dialysis (PD) solutions, including neutral pH, low glucose degrad...
Glucose-based peritoneal dialysis (PD) solutions are the mainstay of therapy for PD patients, yet ar...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...